Company intelligence / Profile preview
Kintor Pharmaceutical Limited
Chinaen.kintor.com.cn ↗
- Ownership
- Private
- Employees
- ~168
- Development stage
- Phase 3
01
Overview
Recent clinical studies show superior efficacy of KX-826 in combination with minoxidil for male adults with AGA in China compared to minoxidil monotherapy. Long-term safety Phase III clinical trial of KX-826 for AGA treatment reached its primary endpoint.
- Therapeutic areas
- OncologyDermatology
- Modalities
- Small moleculesBiologics (monoclonal antibodies)
- Industry
- Biotech
02
Drug pipeline
16 assets15 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Kintor Pharmaceutical Limited.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kintor Pharmaceutical Limited.